JP2022533671A5 - - Google Patents

Info

Publication number
JP2022533671A5
JP2022533671A5 JP2021568852A JP2021568852A JP2022533671A5 JP 2022533671 A5 JP2022533671 A5 JP 2022533671A5 JP 2021568852 A JP2021568852 A JP 2021568852A JP 2021568852 A JP2021568852 A JP 2021568852A JP 2022533671 A5 JP2022533671 A5 JP 2022533671A5
Authority
JP
Japan
Prior art keywords
complex according
cell surface
peptide
linker
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533671A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/034050 external-priority patent/WO2020237078A1/en
Publication of JP2022533671A publication Critical patent/JP2022533671A/ja
Publication of JP2022533671A5 publication Critical patent/JP2022533671A5/ja
Priority to JP2026039007A priority Critical patent/JP2026120533A/ja
Pending legal-status Critical Current

Links

JP2021568852A 2019-05-22 2020-05-21 薬物複合体およびその使用方法 Pending JP2022533671A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026039007A JP2026120533A (ja) 2019-05-22 2026-03-11 薬物複合体およびその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962851443P 2019-05-22 2019-05-22
US62/851,443 2019-05-22
PCT/US2020/034050 WO2020237078A1 (en) 2019-05-22 2020-05-21 Drug conjugates and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026039007A Division JP2026120533A (ja) 2019-05-22 2026-03-11 薬物複合体およびその使用方法

Publications (2)

Publication Number Publication Date
JP2022533671A JP2022533671A (ja) 2022-07-25
JP2022533671A5 true JP2022533671A5 (enExample) 2023-05-26

Family

ID=73458657

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568852A Pending JP2022533671A (ja) 2019-05-22 2020-05-21 薬物複合体およびその使用方法
JP2026039007A Pending JP2026120533A (ja) 2019-05-22 2026-03-11 薬物複合体およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026039007A Pending JP2026120533A (ja) 2019-05-22 2026-03-11 薬物複合体およびその使用方法

Country Status (9)

Country Link
US (1) US20220211861A1 (enExample)
EP (1) EP3972647A4 (enExample)
JP (2) JP2022533671A (enExample)
KR (1) KR20220012278A (enExample)
CN (1) CN113891731A (enExample)
AU (1) AU2020277470A1 (enExample)
CA (1) CA3138933A1 (enExample)
SG (1) SG11202112129SA (enExample)
WO (1) WO2020237078A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3156165A1 (en) * 2019-09-30 2021-04-08 The Board Of Trustees Of The Leland Stanford Junior University Knottin-immunostimulant conjugates and related compositions and methods
WO2023028590A1 (en) 2021-08-27 2023-03-02 Yale University Molecular degraders of extracellular proteins
KR20240099143A (ko) 2021-08-27 2024-06-28 예일 유니버시티 세포외 단백질의 분자 분해제
CA3247329A1 (en) * 2022-02-02 2023-08-10 Cancer Targeted Technology Llc PHOSPHORAMIDATE-BASED SMALL MOLECULE DRUG CONJUGATES TARGETING PSMA
CN119486763A (zh) * 2022-07-14 2025-02-18 苏州宜联生物医药有限公司 抗体药物偶联物及其制备方法和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958957A1 (en) * 2007-02-16 2008-08-20 NascaCell Technologies AG Polypeptide comprising a knottin protein moiety
CA2817197C (en) * 2010-11-08 2020-08-04 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
UA112434C2 (uk) * 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Антигензв'язувальний білок, який специфічно зв'язується з всма
EP2714737A1 (en) * 2011-05-27 2014-04-09 Glaxo Group Limited Bcma (cd269/tnfrsf17) -binding proteins
US9587001B2 (en) * 2012-10-19 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University Conjugated knottin mini-proteins containing non-natural amino acids
EP3180018B1 (en) * 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
BR122020025870B1 (pt) * 2014-12-23 2024-01-09 Nbe-Therapeutics Ag Método para a produção de um conjugado de proteína de ligaçãofármaco
WO2016165762A1 (en) * 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
AU2016283391A1 (en) * 2015-06-26 2017-11-30 Fred Hutchinson Cancer Research Center Therapeutic peptides and methods of use thereof
WO2017139570A1 (en) * 2016-02-12 2017-08-17 Massachusetts Intitute Of Technology Synergistic tumor treatment with il-2, an integrin-binding-fc fusion protein, and a cancer vaccinne
US10765625B2 (en) * 2016-03-15 2020-09-08 The Board Of Trustees Of The Leland Stanford Junior University Knottin-drug conjugates and methods of using the same
US20190292243A1 (en) * 2016-08-22 2019-09-26 Fred Hutchinson Cancer Research Center Peptides and methods of use thereof
EP3568150A4 (en) * 2017-01-10 2020-12-02 Xcella Biosciences, Inc. POLYTHERAPY FOR TUMOR TREATMENT WITH INTEGRIN-BOUND FC FUSION PROTEIN AND IMMUNE MODULATOR
TWI804499B (zh) * 2017-06-23 2023-06-11 美商維洛斯生物公司 Ror1抗體免疫接合物
CA3156165A1 (en) * 2019-09-30 2021-04-08 The Board Of Trustees Of The Leland Stanford Junior University Knottin-immunostimulant conjugates and related compositions and methods
US20230211001A1 (en) * 2020-07-30 2023-07-06 The Board Of Trustees Of The Leland Stanford Junior University Lysosomal Targeting Molecules Comprising Knottin Peptides And Related Compositions And Methods

Similar Documents

Publication Publication Date Title
JP2019172710A5 (enExample)
JP2023512036A5 (enExample)
Maderna et al. Recent advances in the development of new auristatins: structural modifications and application in antibody drug conjugates
Dubowchik et al. Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity
Eras et al. Chemical conjugation in drug delivery systems
Mahato et al. Prodrugs for improving tumor targetability and efficiency
JP2025066807A (ja) 生体直交型組成物
Lu et al. Design of novel bioconjugates for targeted drug delivery
JP2022552839A5 (enExample)
CA2921707C (en) Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
Edupuganti et al. Self-immolative linkers in prodrugs and antibody drug conjugates in cancer treatment
JP2005501052A5 (enExample)
CA2149818C (en) Combination of necrosis-inducing substances with substances which are activated by necroses for the selective therapy of tumors and inflammatory disorders
JP2018504925A5 (enExample)
Brady et al. Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity
Chowdari et al. Uncialamycin as a novel payload for antibody drug conjugate (ADC) based targeted cancer therapy
JP2008515889A5 (enExample)
EP0038357A1 (en) Hydrolytic enzyme-activatible pro-drugs
JP2017061474A5 (enExample)
JP2018520091A5 (enExample)
JP2018520991A5 (enExample)
CA2365533A1 (en) Diagnosis and treatment of neuroectodermal tumors
JP2017521371A5 (enExample)
McGonigle et al. Neuropilin-1 drives tumor-specific uptake of chlorotoxin
WO2005032474A2 (en) Pharmaceutical compositions for prevention of overdose or abuse